Showing results (71-80 of 83) with videos related to
Sort By:
Pageof 9
Medical Sciences (Basel, Switzerland)|April 24, 2026
Survival Outcomes in Lymph Node-Positive Merkel Cell Carcinoma (Stage III): A Comparison Between Known and Unknown Primary Tumors and Their Sun Exposure SitesRonen Brenner, Hanna T Frumin Edri, Sabri El-Saied, et al.Cancers|August 27, 2021
Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic DrugsAbed Agbarya, Ina Sarel, Tomer Ziv-Baran, et al.Frontiers in Oncology|June 1, 2022
The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs)Ari Raphael, Amir Onn, Liran Holtzman, et al.Biomedicines|October 29, 2025
Comparison of Mitotic Count and Ki-67 Index in Grading Gastroenteropancreatic Neuroendocrine Tumors and Their Association with MetastasesMohammad Sheikh-Ahmad, Abed Agbarya, Sharon Talisman, et al.Oncology Nursing Forum|June 21, 2017
Attitudes Among Nurses Toward the Integration of Complementary Medicine Into Supportive Cancer CareEran Ben-Arye, Bella Shulman, Yael Eilon, et al.Biomed Research International|July 11, 2015
Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter StudyRon Epelbaum, Einat Shacham-Shmueli, Baruch Klein, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 4, 2018
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point InhibitorsElizabeth Dudnik, Nir Peled, Hovav Nechushtan, et al.Translational Oncology|November 13, 2020
Long term follow-up of EGFR mutated NSCLC casesGad Rennert, Maya Gottfried, Hedy S Rennert, et al.Clinical Lung Cancer|May 8, 2019
Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life CohortElizabeth Dudnik, Jair Bar, Nir Peled, et al.The Israel Medical Association Journal : IMAJ|December 26, 2021
Oncology Treatments during the COVID-19 Pandemic in Israel: the ONCOR StudyGalit Hirsh-Yechezkel, Angela Chetrit, Sivan Ben Avraham, et al.Pageof 9